AD/PD 2021 | Gamma frequency neuromodulation in AD: results from the Overture study

Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, describes results from the Phase II Overture study (NCT03556280), which evaluated 6 months of gamma frequency neuromodulation in patients with mild-to-moderate Alzheimer’s disease (AD), which was demonstrated to be safe and well tolerated. Interestingly, while the three primary cognitive outcome measures were found to be statistically insignificant in this study, the AD Cooperative Study – Activities of Daily Living (ADSC-ADL) secondary outcome measure showed a statistically significant improvement. There was also a statistically significant benefit on whole brain volume, however this was not seen in hippocampal volume. Together, these results suggest this treatment may have a broader, less AD-specific therapeutic mechanism, although further study is required. This interview took place during the AD/PD™ 2021 conference.